Search research articles
Contact Us
Filters
Showing results (81-90 of 104) with videos related to
Page
of 11
Sort By:
JCO Precision Oncology
|
October 26, 2019
Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making
Derrick L Tao, Shawna Bailey, Tomasz M Beer, et al.
The Oncologist
|
May 11, 2026
A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate Cancer
Julie N Graff, Claire E P Smith, Alexandra O Sokolova, et al.
NPJ Precision Oncology
|
September 13, 2023
Evolution of structural rearrangements in prostate cancer intracranial metastases
Francesca Khani, William F Hooper, Xiaofei Wang, et al.
Cancer Research Communications
|
January 5, 2026
Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
Ya-Mei Hu, Faming Zhao, Julie N Graff, et al.
Cancer Chemotherapy and Pharmacology
|
March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
Fred Saad, Kim N Chi, Neal D Shore, et al.
European Urology
|
September 10, 2020
Apalutamide and Overall Survival in Prostate Cancer
Matthew R Smith, Fred Saad, Simon Chowdhury, et al.
The New England Journal of Medicine
|
February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R Smith, Fred Saad, Simon Chowdhury, et al.
British Journal of Cancer
|
November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
John Shen, Simon Chowdhury, Neeraj Agarwal, et al.
Clinical Genitourinary Cancer
|
June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer
Terence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
J N Graff, M Burotto, P C Fong, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 104) with videos related to
Sort By:
Page
of 11
JCO Precision Oncology
|
October 26, 2019
Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making
Derrick L Tao, Shawna Bailey, Tomasz M Beer, et al.
The Oncologist
|
May 11, 2026
A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate Cancer
Julie N Graff, Claire E P Smith, Alexandra O Sokolova, et al.
NPJ Precision Oncology
|
September 13, 2023
Evolution of structural rearrangements in prostate cancer intracranial metastases
Francesca Khani, William F Hooper, Xiaofei Wang, et al.
Cancer Research Communications
|
January 5, 2026
Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
Ya-Mei Hu, Faming Zhao, Julie N Graff, et al.
Cancer Chemotherapy and Pharmacology
|
March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
Fred Saad, Kim N Chi, Neal D Shore, et al.
European Urology
|
September 10, 2020
Apalutamide and Overall Survival in Prostate Cancer
Matthew R Smith, Fred Saad, Simon Chowdhury, et al.
The New England Journal of Medicine
|
February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R Smith, Fred Saad, Simon Chowdhury, et al.
British Journal of Cancer
|
November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
John Shen, Simon Chowdhury, Neeraj Agarwal, et al.
Clinical Genitourinary Cancer
|
June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer
Terence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
J N Graff, M Burotto, P C Fong, et al.
Page
of 11